Ageless NAD+ Review: A Listed Price, and a Letter Filed Elsewhere

Two things about this company have to be said before anything else, because both of them are the kind of detail a reader would never find on their own.

The first is that Ageless is not AgelessRx. Two different companies sell NAD+ under near-identical names: `tryageless.com`, operating out of Newark, Delaware with a Florida provider group, and `agelessrx.com`, the long-established Ann Arbor longevity clinic. We rank both, separately, and everything on this page is about the first one. Nothing here applies to the second.

The second is that there is a live FDA warning letter behind this brand, and it is filed under a company name the brand does not use on its shop. We come back to it properly below, including why a routine screen would have missed it entirely.

With that said: Ageless has the deepest non-GLP-1 catalogue of any paid row on our board, it names seven dispensing pharmacies in public, and it sells NAD+ in two routes with the milligram strength printed on both. It also publishes a price it tells you in advance may not be the price.

What it actually costs, and why we call it a listing

Ageless's non-GLP-1 line sits on no plan ladder at all. There is no three-month rung, no annual prepay, no membership — each product is a flat one-month purchase from the shop. Read against the rest of our board, where roughly half the advertised figures turn out to be commitment rungs wearing a monthly costume, that is genuinely refreshing.

The listed shop prices are: NAD+ 200 mg troche $149, NAD+ injection $169 for the 1,200 mg "high strength" and $199 for the 1,000 mg, methylene blue 25 mg capsules $149, and MIC+B12 injection $94.

Now the qualifier, which travels with every one of those numbers. Ageless's own product pages state, verbatim: "Exact pricing depends on your prescribed dose. Final amount is shown after clinical review." That sentence is why we call these listings rather than rates. It is not a hidden term — it is on the page — but it means the figure you read is a starting position, not a commitment, and no arithmetic you do in advance survives contact with the prescriber.

Two smaller things sit on top of it. Every product carries a struck-through "was" price and is permanently on sale, so the discount is the standing price rather than an event. And the affiliate landing page runs a countdown timer that reads "Ends in 00 h 00 m 00 s" — permanently expired, which is the same thing as permanently running.

The dose ladder runs backwards

This one is small, checkable and genuinely strange. The 1,200 mg "high strength" NAD+ injection is listed at $169. The 1,000 mg is listed at $199. More milligrams, less money.

We are not going to speculate about why. What matters for a reader is the practical consequence: on Ageless's own shop, the cheaper NAD+ injection is also the stronger one, and any sentence you have read anywhere about "starting low" costs more here than not doing so. It is also a reason to treat the price list as a list rather than a price structure — a catalogue where strength and cost move in opposite directions is not one where the number has been reasoned about.

Compare that with the providers on our board that publish a dose ladder properly. Lttl publishes its entire term ladder rung by rung and charges the same price at every dose. Ageless publishes two strengths at two prices, in the wrong order.

The FDA warning letter

There is a live warning letter connected to this brand, it is not closed out, and finding it requires knowing something the brand does not advertise.

The letter is addressed to "Lovely Meds, Inc. dba Lovely Meds" and was issued in September 2025 by the Center for Drug Evaluation and Research. In the FDA's public warning-letter index, the close-out column for it is empty, which means FDA has not issued a close-out letter. That is the whole disclosure: a letter exists, that is who it was addressed to, that is when, and it has not been closed out. We are not going to characterise what it alleges. That is the FDA's document, and paraphrasing an enforcement action on a page that earns a commission from the company would turn a public record into an accusation of ours. Anyone who wants the substance can search that exact entity string in the FDA's warning-letter database and read it themselves.

What we will say is how the connection is established, because it is not obvious and it is not our inference. Ageless's own regulation page states it: "Try Ageless is a brand operated by Lovely Meds, Inc. The website tryageless.com is managed under this entity." The brand names its operating company three different ways across three of its own pages — a "brand of Lovely Ageless Group" in its terms, a brand operated by Lovely Meds, Inc. on its regulation page, and "Try Ageless, Inc" in its app terms, where it also says it operates the website lovelymeds.com. The letter's addressee is one of those three.

And here is the part worth recording for anyone else who screens providers. The FDA index returns zero results for "tryageless" and zero for the condensed "lovelymeds". Only the spaced form, lovely meds, surfaces the record. A screen run against the domain, or against the company name as the brand writes it in one word, would have come back clean — and clean would have been wrong. We ran it with a known positive control in the same pass so that the zeroes we do report elsewhere on this site mean something.

One more thing that is a fact rather than a characterisation: Ageless makes no mention of the letter anywhere on its own site. Neither does most of this industry, which is the reason we publish the ones we find. A warning letter does not disqualify a provider from our board and never has — three other companies we rank carry one and stay ranked. It is a disclosure obligation, and the obligation is ours.

Where it is unusually good: the supply chain

Ageless names seven dispensing pharmacies: The Pharmacy Hub, Greenwich Rx, VialsRX, Partell Specialty, Believe Rx, Precision Compounding Pharmacy & Wellness, and HealthWarehouse.com. That is more than any other company on our board names — more than Pallas Health's six, more than Breeze Meds' four, and vastly more than the majority, which name none at all.

This matters more than it sounds like it should. When a company names its pharmacy, a reader can check the pharmacy. When it does not, there is nothing to check, and "a licensed U.S. compounding pharmacy" is a sentence that cannot be falsified. One footnote worth knowing, and it cuts against the headline: The Pharmacy Hub, at 15600 NW 15th Avenue in Miami, is the same pharmacy at the same address that Willow and System Labs — two otherwise unrelated companies we also rank — dispense through. Three brands, one dispensary. Seven named pharmacies is a real disclosure and we credit it as one; it is not evidence of seven independent supply chains, and discovering the same facility behind two brands you were comparing is the opposite of a second opinion.

The clinical side is thinner than the pharmacy side but real. Prescribing runs through Wasef Health, PC, and two physicians associated with the operation verify as active in the federal NPPES registry: Michael Wasef, MD (NPI 1417261926, internal medicine, Florida) and Jonah Mink, MD (NPI 1083052351). We checked both against the registry rather than taking the site's word for it, and a fabricated NPI returned nothing in the same pass.

Where it is bad: the pages a reader would use to trust it

The doctors page is unedited template filler. `/medical-experts/` renders a fictional physician — "Jacob Jones" — twice, under two different specialties, and the testimonials beside it use the stock names that ship with the UI kit: Guy Hawkins, Dianne Russell, Ronald Richards. This is the page whose entire job is to make a reader believe there are clinicians behind the prescription, and it was published without being written.

The LegitScript badge does not resolve. The seal ID in the footer returns nothing from LegitScript's own image CDN, and the badge renders as a broken image with zero natural width. A known-good seal from another provider returned a real image in the same pass, so the probe is discriminating and the failure is real. We therefore do not repeat the certification claim for this company. A badge is not a certification; a badge that does not resolve is not even a badge.

It will not say where it ships. No state list exists anywhere on the site — while its own peptide page promises "State-smart — we tell you what's available in your state upfront." It does not.

The refund policy contradicts itself and cites the wrong country. It names two different amounts for the same administrative fee — $200 in one place, $400 in another — and refers to "our registered UK pharmacy", while the main terms disclaim UK and MHRA jurisdiction entirely. Separately, the app terms state that "Try Ageless does not support subscriptions or recurring billing", which is flatly contradicted by the recurring billing configuration on every product.

What it does not sell, whatever the peptide page implies

Ageless runs a page called the peptide founding group listing BPC-157, TB-500, CJC-1295, ipamorelin, tesamorelin and MK-677. None of them is purchasable. There is no price and no cart; the page states they are pending the FDA's July 2026 advisory-committee review of these substances for pharmacy compounding. It is a waitlist, and it should be read as one.

Two liposomal capsule products — glutathione and NAD+ — are listed with no stock, no variant and no price, so they are not purchasable either. What Ageless does sell, and sells properly, is the NAD+ injection and troche, sermorelin in three routes, oral methylene blue, MIC+B12, testosterone and low-dose naltrexone.

One structural note if you are reading the testosterone line: it has no month-to-month option at all. The shortest purchasable term is a three-month prepay, so every per-month TRT figure on that part of the site is a division rather than a price.

The evidence, which does not change for a paid partner

Ageless sells NAD+ on energy and healthy ageing, and our position on that is the same one we apply to every company we rank, including the one we rank first. No rigorous human trial shows that injected or oral NAD+ improves cognition, focus or energy. The best-controlled human data runs the other way: in older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ and did not improve cognition against placebo¹; a second randomised trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit either²; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all³.

The fuller version is in our pillar review of what the NAD+ evidence actually shows, and the precursor literature specifically in what the NMN and NR trials found. The compounded preparations sold here are also not FDA-approved products, and a compounded drug is not a generic equivalent of an approved one⁴.

Who it is for

If you want the widest non-GLP-1 shelf among the companies we are paid by — NAD+ in two routes with strengths published, plus methylene blue, sermorelin and TRT under one login — Ageless has it, and the flat one-month shop structure means you are not signing up to a year to reach the advertised number.

If what you need is a figure you can budget against before you start, this is the wrong shop, and the company says so itself. And if you are deciding partly on trust signals, weigh the seven named pharmacies against a doctors page that was never written, a badge that does not resolve, and a live warning letter behind the operating entity. Those are not the same kind of fact, and they should not cancel each other out in your head.

If the underlying question is whether an injection will lift the fog, the honest starting point is not a shop at all — work through what actually causes brain fog first. Sleep debt, thyroid, iron, B12, alcohol and ordinary medication side effects account for far more of it than a coenzyme does, and every one of them is cheaper to rule out.

The bottom line

Ageless publishes more of its supply chain than anyone else we rank and less of its commercial terms than almost anyone. It lists NAD+ at $149 to $199 and tells you the real number arrives after clinical review. Its stronger injection costs less than its weaker one. Its certification badge does not resolve, its doctors page is filler, and there is a live FDA warning letter — not closed out, issued in September 2025 — addressed to the company its own regulation page names as the operator of the website. We rank it, we link it, and we have told you all of that before you press anything.